Indications

• Chronic Myeloid Leukemia (CML) (see Chronic Myeloid Leukemia, [[Chronic Myeloid Leukemia]])
• Dermatofibrosarcoma Protuberans
• Gastrointestinal Stromal Tumors (GIST)

---

Pharmacology

• Tyrosine Kinase Inhibitor: epidemal growth factor receptor (EGFR) antagonist

---

Administration

• PO

---

Adverse Effects

Cardiology Adverse Effects

• Chest Pain (see Chest Pain, [[Chest Pain]]): occurs in >10% of cases
• Hypotension (see Hypotension, [[Hypotension]]): occurs in >10% of cases (reported cases have been pediatric Philadelphia chromosome-positive ALL cases)
• Pericardial Effusion (see Pericardial Effusion, [[Pericardial Effusion]]): occurs in >10% of cases
• Peripheral Edema (see Peripheral Edema, [[Peripheral Edema]]): occurs in >10% of cases

Dermatologic Adverse Effects

• Dermatitis: occurs in >10% of cases
• Eczema: occurs in >10% of cases
• Facial/Periorbital Edema: occurs in >10% of cases
• Rash: occurs in >10% of cases

Gastrointestinal Adverse Effects

• Abdominal Pain (see Abdominal Pain, [[Abdominal Pain]]): occurs in >10% of cases
• Ascites (see Ascites, [[Ascites]]): occurs in >10% of cases
• Diarrhea (see Diarrhea, [[Diarrhea]]): occurs in >10% of cases
• Dyspepsia (see Dyspepsia, [[Dyspepsia]]): occurs in >10% of cases
• Nausea/Vomiting (see Nausea and Vomiting, [[Nausea and Vomiting]]): occurs in >10% of cases
• Weight Gain (see Weight Gain, [[Weight Gain]]): occurs in >10% of cases

Hematologic Adverse Effects

• Hemorrhage: occurs in 3-53% of cases
• Myelosuppression: occurs in >10% of cases
  • Anemia: occurs in 25-80% of cases
  • Leukopenia: occurs in 5-47% of cases
  • Neutropenia: occurs in 12-16% of cases
  • Thrombocytopenia: occurs in 1-31% of cases

Neurologic Adverse Effects

• Anxiety (see Anxiety, [[Anxiety]]): occurs in 8-12% of cases
• Depression (see Depression, [[Depression]]): occurs in <15% of cases
• Dizziness (see Dizziness, [[Dizziness]]): occurs in 5% to 19% of cases
• Fatigue (see Fatigue, [[Fatigue]]): occurs in >10% (29-75%) of cases
• Headache (see Headache, [[Headache]]): occurs in >10% (8-35%) of cases
• Insomnia (see Insomnia, [[Insomnia]]): occurs in 10-15% of cases
• Parasthesias (see Parasthesias, [[Parasthesias]]): occurs in <12% of cases

Otolaryngologic Adverse Effects

• Pharyngitis/Laryngitis (see Pharyngitis, [[Pharyngitis]]): occurs in >10% cases
• Rhinitis (see Rhinitis, [[Rhinitis]]): occurs in >10% cases
• Sinusitis (see Acute Rhinosinusitis, [[Acute Rhinosinusitis]]): occurs in 4% to 11% of cases
• Upper Respiratory Tract Infection: occurs in 3% to 21% of cases

Pulmonary Adverse Effects

• Cough (see Cough, [[Cough]]: occurs in 11-27% of cases
• Drug-Induced Pulmonary Eosinophilia (see Drug-Induced Pulmonary Eosinophilia, [[Drug-Induced Pulmonary Eosinophilia]])
• Dyspnea (see Dyspnea, [[Dyspnea]]): occurs in <21% of cases
• Interstitial Pneumonitis (see Interstitial Lung Disease-Etiology, [[Interstitial Lung Disease-Etiology]])
• Pneumonia (see Pneumonia, [[Pneumonia]]): occurs in 4-13% of cases (reported cases have been in CML)
• Pulmonary Edema (see Acute Lung Injury-ARDS, [[Acute Lung Injury-ARDS]]): occurs in >10% of cases

Rheumatologic/Orthopedic Adverse Effects

• Bone Pain: occurs in >10% of cases
• Joint Pain: occurs in >10% of cases
• Muscle Spasms/Cramps: occurs in >10% of cases
• Myalgias (see Myalgias, [[Myalgias]]): occurs in >10% of cases

Other Adverse Effects

• Chills: occurs in <11% of cases
• Fever (see Fever, [[Fever]]): occurs in 6% to 41% of cases
• Flu-Like Symptoms: occurs in 1% to 14% of cases
• Rigors: occurs in 10-12% of cases
• xxx
• xxx

---

References

• Gleevec (imatinib) dosing, indications, interactions, adverse effects, and more. Medscape Reference. WebMD. Retrieved 24 January 2014
• GLEEVEC (imatinib mesylate) tablet [Novartis Pharmaceuticals Corporation]. DailyMed. Novartis Pharmaceuticals Corporation. October 2013. Retrieved 24 January 2014
• GLIVEC Tablets – Summary of Product Characteristics (SPC). electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd
• GLIVEC (imatinib) (PDF). TGA eBusiness Services. Novartis Pharmaceuticals Australia Pty Ltd. 21 August 2013. Retrieved 24 January 2014.
• Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3